A lawsuit seeking damages from Orexigen Therapeutics Inc.'s board for sharing confidential information about an unfinished obesity drug trial fails to connect the leaks to any improper intent, a directors' attorney said in arguing for dismissal of the case Friday in Delaware Chancery Court.
The Texas Supreme Court on Friday decided to end a case asking when the clock begins to run on a personal injury claim stemming from an allegedly defective product, after the plaintiff in a Johnson & Johnson unit pelvic mesh suit dropped her connected Eleventh Circuit appeal.
AngioScore Inc. and TriReme Medical LLC have settled a breach of duty and patent infringement suit over the design of a heart catheter after the Federal Circuit overturned a $20 million judgment in AngioScore’s favor, the companies told a California federal court Thursday.
Shares of venture-backed e-commerce startup Stitch Fix Inc. barely gained on Friday after pricing a downsized $120 million initial public offering, making it one of five issuers spanning the technology, real estate, banking and life science sectors to debut on public markets.
The recent exclusion of two expert witnesses for a customer alleging Colgate-Palmolive Co.’s talcum powder contained asbestos that caused her mesothelioma means Colgate should not face trial in the matter, the company told a Philadelphia judge on Thursday.
The last several weeks have seen the health and life sciences teams at Hogan Lovells, Jones Day, Morgan Lewis & Bockius LLP and Berkeley Research Group LLC grow, with newcomers from the ranks of Medtronic Inc., BakerHostetler, the U.S. Department of Health and Human Services Office of Inspector General and elsewhere.
The U.S. Patent and Trademark Office filed its opening brief Thursday at the Federal Circuit in a closely watched case over its new stance that applicants who appeal to a district court must pay the agency’s legal bills regardless of who wins the case.
Cases alleging talcum powder causes ovarian cancer have exploded in recent years, with thousands of plaintiffs filing suit in hope of following the massive multimillion dollar verdicts against Johnson & Johnson in Missouri and California, but these claims carry no water in other courts, and experts researching the issue are divided on which side the science supports.
In this week’s Taxation With Representation, Marathon Petroleum dropped down $8.1 billion in assets to its master limited partnership, Caesars Entertainment acquired Centaur for $1.7 billion, Shanghai Pharma snapped up the China business of Cardinal Health for $557 million, and OMERS bought Trescal in a $788.6 million deal.
The Winnemucca Shoshoni MBS tribe, American States University and others asked a California federal judge Thursday to stop San Joaquin County from enforcing a new ordinance that halted the cultivation of industrial hemp and led the county and the U.S. Drug Enforcement Administration to seize $77 million worth of their crops.
Hospital technology company Draeger Inc. can't escape a suit brought by Chicago’s Rush University Medical Center that claims Draeger's patient monitoring system Rush purchased for $18 million in 2011 was ineffective and put patients at risk, an Illinois federal judge ruled Thursday.
The U.S. on Wednesday slammed Pfizer's appeal to the Second Circuit of a district court order dismissing its $8.3 million interest suit, saying the pharmaceutical giant brought its action in the wrong court and after the proper statute of limitations period had passed.
A NantKwest shareholder filed a derivative suit Thursday against company insiders, saying the board knew the company was misrepresenting tens of millions of dollars in compensation but hid it from shareholders and continued to try to cover it up afterward.
An auditor who did work for Martin Shkreli-founded Retrophin Inc. on Thursday told jurors in the trial of the controversial pharmaceutical executive’s former Katten Muchin attorney that he didn’t believe there was anything wrong with a series of settlements with investors in Shkreli's MSMB hedge funds that prosecutors say were fraudulent.
The U.S. Senate on Thursday unanimously approved the nearly $700 billion 2018 National Defense Authorization Act, sending the legislation to be signed into law alongside a companion bill intended to address concerns about the U.S. Department of Defense exercising oversight of drugs and medical devices.
Insys Therapeutics Inc. founder John N. Kapoor pled not guilty on Thursday to orchestrating a national scheme to bribe doctors to needlessly prescribe his company’s unique and powerful opioid painkiller that is sprayed under the tongue.
The Patent Trial and Appeal Board's chief judge said Thursday that he wants to debunk the notion that patent owners are getting "gang tackled” as the PTAB receives more review petitions than ever, arguing that 84 percent of the time a single petitioner challenges the patent.
In a precedential ruling Thursday, the Third Circuit affirmed a Pennsylvania federal judge’s dismissal of a False Claims Act lawsuit against CVS Caremark Corp., finding that although the lower court’s reasoning was wrong, the whistleblower failed to show the alleged misrepresentations were important to the government’s decision to pay claims under Medicare Part D.
A Pennsylvania state judge said Wednesday that, for now, he would not allow jurors in an ongoing trial over injuries allegedly caused by the blood thinner Xarelto to hear from a Janssen Pharmaceuticals Inc. sales representative suspected of trying to influence a doctor’s testimony in the case.
A Massachusetts federal judge on Thursday refused to trim a lawsuit alleging insider trading by two former employees of Akebia Therapeutics Inc. and Merrimack Pharmaceuticals Inc.
Federal courts across the country are handing down important rulings interpreting the U.S. Supreme Court’s landmark decision on False Claims Act liability in Universal Health Services v. Escobar. As the rulings keep pouring in, stay up to speed on Law360’s latest coverage and analysis of Escobar’s impact.
Courts have consistently held that social media accounts are subject to established discovery principles but are reluctant to allow parties to rummage through private social media accounts. Recent case law confirms that narrowly tailored information requests get the best results, say Matthew Hamilton, Donna Fisher and Jessica Bae of Pepper Hamilton LLP.
Following the U.S. Supreme Court's decision this year in Impression Products v. Lexmark, companies — particularly pharmaceutical companies — should look to obtain multiple distinct patents with method-of-use claims in order to insulate at least part of their patent portfolios from the defense of patent exhaustion, say Jorge Goldstein and Neil Shull of Sterne Kessler Goldstein & Fox PLLC.
A California court recently held that it has specific personal jurisdiction over nonresident defendants for nonresident plaintiffs’ claims, because the defendants had contracts with two California consultants on the design of the hip implant at issue. This case could lead to more plaintiffs using consulting contracts to subject defendants to suit in particular jurisdictions, says Anne Gruner of Duane Morris LLP.
In the past two years, we witnessed a wave of putative class actions filed under Illinois’ Biometric Information Privacy Act, with the rate of filings increasing exponentially in recent months. Insurers should take note of their potential coverage obligations under various policies, say Jonathan Schwartz and Colin Willmott of Goldberg Segalla LLP.
Jeh Johnson, the former secretary of homeland security, was kind enough to let me visit him to reflect on his diverse career. He told stories that left me speechless. And yes, the man who was responsible for the Transportation Security Administration removed his shoes when going through airport security. You bet I asked, says Randy Maniloff of White and Williams LLP.
Attorneys should follow seven key points to ensure that their discovery requests and pleadings are appropriately prepared to overcome common hurdles that may be encountered when requesting production of a personnel file, say Michael Errera and Paul Ferland of Foran Glennon Palandech Ponzi & Rudloff PC.
California Gov. Jerry Brown recently signed SB-17, a law intended to foster transparency in connection with drug pricing and its impact on insurance costs. The law imposes significant new reporting requirements on many drug manufacturers, pharmacy benefit managers, and health care service plans and health insurers operating in California, say attorneys with Ropes & Gray LLP.
A recent China Food and Drug Administration Office circular outlines a series of robust reform initiatives that will likely transform the competitive dynamics in China's life sciences industry and considerably impact pharmaceutical and device companies' strategies in the Chinese market, say Katherine Wang and Silvia Mo of Ropes & Gray LLP.
While Alexander Hamilton is the subject of a hit Broadway musical and renewed biographical examinations, professor Kate Brown takes us down a road less traveled in her book "Alexander Hamilton and the Development of American Law" — showing Hamilton as first, last and foremost an American lawyer, says U.S. District Judge Rodney Gilstrap of the Eastern District of Texas.
In a recent ruling, the Fifth Circuit found that a plaintiff who failed to pursue discovery of withheld documents was not entitled to relief from summary judgment in favor of the defendant. Keeping discovery responses specific and narrow puts the onus on your adversary to follow up as cases develop, says Alexis Kellert of Weil Gotshal & Manges LLP.